Arrowhead Pharmaceuticals, Inc. Aktie News

PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it has dosed the first subjects in a Phase 1/2a clinical trial of ARO-MAPT, the company's investigational RNA interference (RNAi) therapeutic being developed as a potential treatment for tauopathies including Alzheimer's disease, a progressive neurodegenerative disease characterized ...

PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that the United States Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to investigational plozasiran as an adjunct to diet to reduce triglyceride (TG) levels in adults with severe hypertriglyceridemia (SHTG) (TG levels greater than or equal to 500 mg/dL). T...

PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it is scheduled to participate in the following upcoming events: Piper Sandler 37th Annual Healthcare Conference – December 2-4, 2025 Type: Fireside Chat Presentation Date/Time: December 3, 2025, 10:30 a.m. EST 8th Annual Evercore Healthcare Conference – December 2-4, 2025 Type: Fire...

Listen on the go! A daily podcast of Wall Street Breakfast will be available by 8:00 a.m.

Arrowhead Pharmaceuticals, Inc. ( ARWR ) TD Cowen Treatment Advancements in Obesity and Related Disorders Summit November 24, 2025 1:30 PM EST Company Participants James Hamilton - Chief Medical Officer and Head of R&D Conference Call Participants Joseph Thome - TD Cowen, Research Division Presentation Joseph Thome TD Cowen, Research Division Everyone, and thank you for joining us at TD Cowen's...

The biotech published its latest set of annual results. It's now got several revenue streams that are already significantly boosting the fundamentals.

Arrowhead Pharmaceuticals, Inc. ( ARWR ) Q4 2025 Earnings Call November 25, 2025 4:30 PM EST Company Participants Vincent Anzalone - Head of Investor Relations & VP Dr. Christopher Anzalone - Chairman, CEO & President Bruce Given - Chief Medical Scientist Andy Davis - SVP of Cardiovascular & Head of Metabolic Franchise James Hamilton - Chief Medical Officer and Head of R&D Daniel Apel - Chief F...

PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced financial results for its 2025 fiscal year ended September 30, 2025. The Company is hosting a conference call today, November 25, 2025, at 4:30 p.m. ET to discuss the results. “The recent FDA approval of REDEMPLO, indicated as an adjunct to diet to reduce triglycerides in adults with fami...